Trial Profile
A study evaluating effect of Upadacitinib on pharmacokinetics of sensitive probe substrates for CYP enzymes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2018
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Vitamin K; Warfarin
- Indications Ankylosing spondylitis; Atopic dermatitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- 27 Mar 2018 New trial record
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics